Comparison of doctor and patient assessments of asthma control

INTRODUCTION: The objective of asthma management is to control the condition. However, world-wide surveys reveal that only 5% of asthmatics are well controlled. One reason for this phenomenon is the fact that patients and doctors consistently over-estimate control. This study compared patient and doctor assessment of asthma control. METHODS: A random sample of asthmatics was identified by practitioners in South Africa. Patients completed an Asthma Control Test (ACT) and provided a list of medications currently being taken. The doctor also provided an assessment of control which was summarised into the categories - ’not controlled’ and ’controlled’ and listed all medications prescribed. RESULTS: The mean ACT score was 12.8 where doctors assessed the patients as being ‘not controlled’ and 20.7 where doctors assessed the patients as being ‘controlled’. Half of the patients classified themselves as being ‘not controlled’ (ACT score <20, category 1), while doctors classified only 33% of patients as being ‘not controlled’. Although only 7% of patients disagreed with the doctor’s classification of ‘not controlled’, 29% disagreed with the doctor’s assessment of being ‘controlled’. There was a significant difference in ACT score between the sexes (p < 0.0001). Most therapeutic interventions (with the exception of combination products [ICS þ LABA]) performed poorly with regard to level of control. CONCLUSION: This study suggests that asthma still appears to be relatively poorly controlled in South Africa, although levels of patient control appear to have improved compared to previous surveys, and confirms that physicians and patients differ in their assessments of asthma control.The study was funded by an unrestricted financial grant from Glaxo SmithKline

Maraviroc for previously treated patients with R5 HIV-1 infection

Background CC chemokine receptor 5 antagonists are a new class of antiretroviral agents.Methods We conducted two double- blind, placebo- controlled, phase 3 studies - Maraviroc versus Optimized Therapy in Viremic Antiretroviral Treatment- Experienced Patients ( MOTIVATE) 1 and MOTIVATE 2 - with patients who had R5 human immunodeficiency virus type 1 ( HIV- 1) only. They had been treated with or had resistance to three antiretroviral- drug classes and had HIV- 1 RNA levels of more than 5000 copies per milliliter. The patients were randomly assigned to one of three antiretroviral regimens consisting of maraviroc once daily, maraviroc twice daily, or placebo, each of which included optimized background therapy ( OBT) based on treatment history and drug- resistance testing. Safety and efficacy were assessed after 48 weeks.Results A total of 1049 patients received the randomly assigned study drug; the mean baseline HIV- 1 RNA level was 72,400 copies per milliliter, and the median CD4 cell count was 169 per cubic millimeter. At 48 weeks, in both studies, the mean change in HIV- 1 RNA from baseline was greater with maraviroc than with placebo: - 1.66 and - 1.82 log(10) copies per milliliter with the once- daily and twice- daily regimens, respectively, versus - 0.80 with placebo in MOTIVATE 1, and - 1.72 and - 1.87 log(10) copies per milliliter, respectively, versus - 0.76 with placebo in MOTIVATE 2. More patients receiving maraviroc once or twice daily had HIV- 1 RNA levels of less than 50 copies per milliliter ( 42% and 47%, respectively, vs. 16% in the placebo group in MOTIVATE 1; 45% in both maraviroc groups vs. 18% in MOTIVATE 2; P&lt; 0.001 for both comparisons in each study). The change from baseline in CD4 counts was also greater with maraviroc once or twice daily than with placebo ( increases of 113 and 122 per cubic millimeter, respectively, vs. 54 in MOTIVATE 1; increases of 122 and 128 per cubic millimeter, respectively, vs. 69 in MOTIVATE 2; P&lt; 0.001 for both comparisons in each study). Frequencies of adverse events were similar among the groups.Conclusions Maraviroc, as compared with placebo, resulted in significantly greater suppression of HIV- 1 and greater increases in CD4 cell counts at 48 weeks in previously treated patients with R5 HIV- 1 who were receiving OBT. (ClinicalTrials. gov numbers, NCT00098306 and NCT00098722.)